Press releases
Sep 8, 2025
NRG Therapeutics Announces Oversubscribed £50m ($67m) Series B Financing to Deliver Clinical Data in Parkinson’s and Proof of Concept in ALS/MND
Oct 31, 2024
NRG Therapeutics Selects First Development Candidate, NRG5051, and Secures Grant from The Michael J. Fox Foundation for Development of mPTP Inhibitors to Treat Neurodegenerative Diseases
Sep 5, 2024
NRG Therapeutics Awarded Grant Funding from Target ALS to Support the Development of mPTP Inhibitors as Novel Treatments for ALS/MND
Apr 19, 2023
NRG Therapeutics Appoints Vad Lazari Ph.D. as Vice President of Biology to Advance its Mitochondrial Therapeutics for Neurodegenerative Disorders
Feb 22, 2023
NRG Therapeutics Awarded Second $500K Grant from The Michael J. Fox Foundation to Further Progress Parkinson’s Programme
Feb 9, 2023
NRG Therapeutics Appoints Gilles Ouvry Ph.D. as Vice President of Chemistry to Advance its Mitochondrial Therapeutics for Neurodegenerative Disorders
Nov 9, 2022
NRG Therapeutics Announces £16 million Series A to Advance Mitochondrial Therapeutics for Parkinson’s and ALS
Jun 30, 2022
NRG Therapeutics Selects Domainex to be its Integrated Drug Discovery Partner for its Biomedical Catalyst Funded Parkinson’s Disease Project...
May 30, 2022
NRG Therapeutics Announces £2.68M Innovate UK Award to Develop New Medicines to Treat Parkinson’s and Motor Neurone Disease...
Mar 1, 2022
NRG Therapeutics Completes MND Therapeutic Analysis Project with Medicines Discovery Catapult Supported by an Innovate UK EDGE Grant
Dec 16, 2021
NRG Therapeutics Launches MND Drug Discovery Programme and Announces new Collaboration in Australia
Aug 23, 2021
Parkinson’s UK invests a further £490k in NRG Therapeutics to Progress Parkinson’s Drug Discovery Programme
Jul 29, 2021
NRG Therapeutics Awarded $500K Grant from The Michael J. Fox Foundation to Progress Parkinson’s Programme
Jul 1, 2019
Charity invests £1 million to develop a treatment to slow down progression of Parkinson’s
